- Home
- Automated
- NDF A-Z listing
- Alirocumab [Praluent]
A
Alirocumab [Praluent]
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Alirocumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
02/01/2024 PCSK9 inhibitors for treating hypercholesterolaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Evolocumab 140 mg/mL solution for injection in prefilled autoinjector for treating:
non-familial hypercholesterolaemia (non-FH) or mixed dyslipidaemia, with atherosclerotic cardiovascular disease (ASCVD) and additional risk factors and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy (LLT) for at least 12 weeks; or
heterozygous familial hypercholesterolaemia (HeFH), with ASCVD and LDL-c level above 1.8 mmol/L despite maximal tolerated LLT for at least 12 weeks; or
HeFH, without ASCVD, and LDL-c level above 2.6 mmol/L despite maximal tolerated LLT for at least 12 weeks; or
homozygous familial hypercholesterolaemia (HoFH) with LDL-c level above 1.8 mmol/L despite maximal tolerated statin-lowering therapy for at least 12 weeks.
Funding status
[R] Evolocumab 140 mg/mL solution for injection in prefilled autoinjector is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2023.
[R] The dose of evolocumab for the treatment of non-FH or mixed dyslipidaemia and HeFH recommended for subsidy is 140 mg every 2 weeks. The dose restriction does not apply to HoFH.
[R] Evolocumab should be used in line with the additional clinical criteria listed in the Annex.
[NR] MAF assistance does not apply to any formulations or strengths of alirocumab or inclisiran for treating hypercholesterolaemia.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Praluent Injection, Solution (Prefilled Pen) 75 mg/mL |
|
Praluent Injection, Solution (Prefilled Pen) 150 mg/mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |